Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Combo Product Firms Lose Patience As Regs, Guidance Are Delayed Again

This article was originally published in The Pink Sheet Daily

Executive Summary

Industry firms especially eager to see proposed GMP and adverse event reporting rules.

You may also be interested in...



President Obama Freezes Pending Bush Regulations For Review

In one of his first acts after taking office, President Obama temporarily halted issuance of regulations from all federal departments and agencies until his own appointees have signed off on the rules

Imaging Industry Wants A Rewrite On FDA Contrast Indication Guidance

An FDA draft guideline outlining the regulatory pathway for imaging equipment makers seeking to add new contrast agent indication labeling needs an overhaul to include more explicit guidance for sponsors, manufacturers say

Industry Looks To FDA’s New Combo Products Chief For Answers

FDA's Office of Combination Products says it is getting back on track with new leadership in place after months of flux. Industry meanwhile is pushing the office to accelerate the release of rules and guidelines to help companies navigate the relatively new area of regulation

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069031

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel